NICE approves nivolumab for Hodgkin's lymphoma

NICE approves nivolumab for Hodgkin's lymphoma PharmacoEconomics & Outcomes News 784, p33 - 12 Aug 2017 NICE approves nivolumab for Hodgkin’s lymphoma NICE has approved nivolumab [Opdivo, Bristol-Myers Squibb] for treating Hodgkin’s lymphoma in patients whose cancer is progressing despite undergoing autologous stem cell transplant and treatment with brentuximab vedotin. Bristol-Myers Squibb estimates that around 30 patients a year with Hodgkin lymphoma could benefit from nivolumab in the first year, with the drug keeping them well enough to have a stem cell transplant from another person’s healthy cells and potentially curing the disease. Commenting on the decision, Director of the Centre for Health Technology Evaluation at NICE Professor Carole Longson, said "these patients with Hodgkin lymphoma often have a poor prognosis with limited options left. Nivolumab offers them a promising treatment and our committee were able to recommend the drug as a cost effective use of NHS resources". NICE. NICE approval for nivolumab provides new treatment for advanced blood cancer. Internet Document : 26 Jul 2017. Available from: URL: https:// www.nice.org.uk/news/article/nice-approval-for-nivolumab-provides-new- treatment-for-advanced-blood-cancer 803261759 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

NICE approves nivolumab for Hodgkin's lymphoma

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/nice-approves-nivolumab-for-hodgkin-s-lymphoma-NgI0OQun88
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4244-9
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p33 - 12 Aug 2017 NICE approves nivolumab for Hodgkin’s lymphoma NICE has approved nivolumab [Opdivo, Bristol-Myers Squibb] for treating Hodgkin’s lymphoma in patients whose cancer is progressing despite undergoing autologous stem cell transplant and treatment with brentuximab vedotin. Bristol-Myers Squibb estimates that around 30 patients a year with Hodgkin lymphoma could benefit from nivolumab in the first year, with the drug keeping them well enough to have a stem cell transplant from another person’s healthy cells and potentially curing the disease. Commenting on the decision, Director of the Centre for Health Technology Evaluation at NICE Professor Carole Longson, said "these patients with Hodgkin lymphoma often have a poor prognosis with limited options left. Nivolumab offers them a promising treatment and our committee were able to recommend the drug as a cost effective use of NHS resources". NICE. NICE approval for nivolumab provides new treatment for advanced blood cancer. Internet Document : 26 Jul 2017. Available from: URL: https:// www.nice.org.uk/news/article/nice-approval-for-nivolumab-provides-new- treatment-for-advanced-blood-cancer 803261759 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off